Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
ProShares UltraShort Nasdaq Biotechnology(BIS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BIS
10/14/2026: BIS (1-star) is currently NOT-A-BUY. Pass it for now.
ProShares UltraShort Nasdaq Biotechnology (BIS) is a leveraged ETF designed to deliver -2x the daily return of the Nasdaq Biotechnology Index. It provides active traders with an efficient, margin-free way to profit from or hedge against declines in the biotech sector. Due to daily compounding, it is subject to significant tracking error over long periods and is not appropriate for buy-and-hold strategies. Primary risks include extreme volatility and potential capital loss during sector rallies. The fund is best suited for experienced, short-term tactical traders who closely monitor daily index moves.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | This fund is designed for short-term tactical hedging rather than long-term growth participation. |
| Momentum investor | Strong fit while signal remains positive | Momentum traders may use this fund when the underlying index shows clear signs of a downward trend. |
| Value investor | Weak fit | Value investors generally seek long-term fundamental quality, which is incompatible with daily leveraged inverse strategies. |
| Dividend/Income investor | Weak fit | This ETF does not provide income and is not suitable for dividend-focused portfolios. |
| Low-risk investor | Weak fit | The high leverage and inverse nature make this product extremely high-risk. |
Investor Profile
Ideal Investor Profile
Sophisticated, active traders with a high risk tolerance and deep understanding of daily-reset leveraged products.
Suitability
Strictly for short-term tactical trading; not suitable for long-term investors or passive index followers.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | The -2x leverage multiplier significantly amplifies daily swings in the underlying index. |
| Market risk | High | Adverse moves in the biotech sector are magnified, leading to rapid potential losses. |
| Concentration | High | Exposure is limited to a single sector, which can be highly sensitive to clinical trial and regulatory news. |
| Tracking/expense | High | Compounding effects cause the fund to diverge from the index over periods longer than one day. |
| Liquidity | Medium | Trading costs can increase significantly during market stress or low volume periods. |
| Business/sector quality | Medium | Biotech is inherently risky due to the binary nature of drug development success. |
Risk Analysis
Volatility
Extreme, as the fund is designed to double the daily price action in the opposite direction.
Market Risk
High sensitivity to biotech sector news, including drug approvals and FDA decisions.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Derivatives | Nasdaq Biotechnology Index (seeks -2x daily return) | 95 | The fund uses derivative contracts to provide inverse exposure to the performance of biotechnology stocks. |
| Cash/collateral | Cash and Cash Equivalents | 5 | Cash is held to serve as collateral for the swap agreements used to achieve the fund's objective. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type ETF | Historic Profit -20.62% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | ETF Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2026 |
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.